Healthcare Industry News: bifurcation
News Release - October 16, 2007
TriReme Medical Inc. Announces $15.5 Million Series C Financing
PLEASANTON, Calif., Oct. 16 (HSMN NewsFeed) -- TriReme Medical Inc. (TMI), a developer of novel stents and stent delivery systems for vascular lesions at or near bifurcations, announced today the successful completion of its $15.6 million Series C financing led by Three Arch Partners and completed by Adams Street Partners. Joining the Company's Board of Directors will be Mark Wan of Three Arch Partners and Michael Lynn, MD, of Adams Street Partners. The funds will be used to continue the development of the company's novel stent system and to support ongoing clinical studies. "We are thrilled to have the support of such a premier group of investors with vast experience and deep understanding of the medical device space," said Eitan Konstantino, PhD, President and CEO of TMI.TMI's stent technology may be useful in more than 25% of the 2.2 million angioplasty procedures performed annually worldwide. TMI's innovative technology is designed to provide the interventional cardiologist with the ease of use, high deliverability and low profile of a main vessel stent in a device that is designed to effectively scaffold the ostium, or the junction of main and side branches in a coronary vessel. TMI's proprietary system has a lower profile than standard bifurcation stent systems and even some of the leading "workhorse" drug eluting stents used for routine, non-bifurcated lesions. Additionally, the delivery system is the only one that allows the physician to actively determine the orientation of the stent prior to deployment and ensure precise stent positioning.
"The TMI system is a user-friendly, single-balloon bifurcation stent system that provides the interventional cardiologist with a high performance tool to help address this unmet clinical need," said Dr. Lynn. William T. Harrington, MD, of Three Arch Partners, commented, "Technology and procedures currently used to treat these bifurcation lesions are clumsy and unnecessarily complex. The TMI solution is elegant, flexible and as easy to use as any stent on the market today. We have been very impressed by the progress of the company to date, particularly the clinical results and the simplified procedure that was developed for the treatment of those complex lesions."
About TriReme Medical Inc.
TriReme Medical Inc. is a privately held medical device company based in Pleasanton, California and dedicated to the development and manufacturing of novel stent technology for the treatment of atherosclerotic disease at or near bifurcations. TMI can be contacted at +1 (925) 931-1300 or info@trirememedical.com.
Source: TriReme Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
